ATRC vs JNJ
ATRC: AtriCure is a leading surgical device company treating atrial fibrillation and post-operative pain through minimally invasive cardiac ablation and cryotherapy technologies. JNJ: A global healthcare leader spanning pharmaceuticals, medical devices, and consumer health products, with a portfolio spanning acute care, oncology, immunology, cardiovascular, and infectious disease.
Side-by-side fundamentals
| Metric | ATRC | JNJ | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $33.52 | $255.63 | |
| Market cap as of 2026-07-23 | $1.7B | $614.6B | |
| P/E as of 2026-07-23 | n/a | 29.22 | |
| PEG as of 2026-07-23 | n/a | 3.16 | |
| Net margin as of 2026-07-23 | -0.8% | +21.5% | JNJ higher |
| Gross margin as of 2026-07-23 | +75.6% | +68.0% | ATRC higher |
| Operating margin as of 2026-07-23 | -0.5% | +25.7% | JNJ higher |
| ROE as of 2026-07-23 | -0.9% | +26.3% | JNJ higher |
| ROA as of 2026-07-23 | -0.7% | +10.7% | JNJ higher |
| Debt / equity as of 2026-07-23 | 0.14 | 0.68 | ATRC lower |
| Revenue growth (YoY) as of 2026-07-23 | +15.0% | +8.1% | ATRC higher |
| Revenue CAGR (3y) SEC XBRL | +17.4% | +6.2% | ATRC higher |
| Dividend yield as of 2026-07-23 | n/a | +2.1% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-23 | 1.25 | 0.23 | |
| 1-year return as of 2026-07-22 close | +18.0% | +52.2% | JNJ higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.